贝塔抑制剂和母乳养:一个现实生活前性研究
Romane Freppel1, Louise Gaboriau2, Marjorie Richardson3
1Centre de Pharmacovigilance Et de Pharmacoépidémiologie, Service de Pharmacologie Médicale, CHU de Lille, Lille, France. romane.freppel@chu-dijon.fr.
European journal of clinical pharmacology
|September 11, 2024
概括
对于患有心脏病的孕妇来说,在母乳养期间使用β-阻断剂往往是令人担忧的. 这项研究发现,虽然一些妇女因β-阻断剂而停止母乳养,但在新生儿中没有观察到严重的不良影响,这表明这是一种一般安全的做法.
科学领域:
- 心脏病学 心脏病学
- 产科 产科 产科 产科 产科
- 药理学 药理学是指药理学的学科.
- 新生儿科学 新生儿科学
背景情况:
- 孕妇的复杂心血管病理需要谨慎的药物管理.
- 贝塔抑制剂经常被处方,但母乳养兼容性数据有限,这引发了对婴儿安全的担忧.
- 多学科的怀孕心脏小组对于管理这些复杂的病例至关重要.
研究的目的:
- 评估接受β-阻断剂治疗的母乳养妇女的比例.
- 通过母乳养暴露于β-阻断剂的新生儿的不良影响的监测.
- 评估在患有心血管疾病的妇女母乳养期间使用β-阻断剂的安全性.
主要方法:
- 从2017年12月到2021年12月进行了前性描述性研究.
- 用β-阻断剂治疗的患有心血管疾病的孕妇患者被多学科心脏团队跟踪.
- 对母亲和新生儿进行了药监督后续检查.
主要成果:
- 69.8%的妇女打算在服用β-阻断剂时进行母乳养.
- 49%的妇女没有母乳养,其中10人引用了理论上的β-阻断剂不兼容性.
- 在那些母乳养的患者中,30%使用了理论上不兼容的β-阻断剂; 56%更换了安全母乳养的药物. 在新生儿中没有报告严重的不良反应.
结论:
- 这项研究代表了在患有心血管疾病的妇女母乳养期间使用β-阻断剂的最大系列.
- 药物可以成为母乳养的障碍,但β-阻断剂对婴儿来说通常是安全的.
- 现有的数据,包括这项研究的结果,对母乳养期间使用β-阻断剂令人放心.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
543
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
543
Adrenergic Antagonists: ɑ and β-Receptor Blockers
420
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
420
Antihypertensive Drugs: Types of β-Blockers
603
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
603
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
548
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
548
Heart Failure Drugs: β-Blockers
321
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
321
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719


